Global Actinic Keratosis Drugs Market 2017-2021

  • ID: 4430373
  • Report
  • Region: Global
  • 80 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Almirall
  • Biofrontera
  • GALDERMA
  • LEO Pharma
  • Novartis
  • Perrigo
  • MORE
About Actinic Keratosis Drugs

Actinic keratosis is a pre-stage non-melanoma skin cancer caused by exposure to ultraviolet (UV) rays. Initially, the skin has a sandpaper-like texture with lesions. It can develop into squamous cell carcinoma, if not treated. The actinic keratosis drugs market includes nucleoside metabolic inhibitors, photosensitizers, nonsteroidal anti-inflammatory drugs (NSAIDs), and immunomodulators.

The analysts forecast the global actinic keratosis drugs market to grow at a CAGR of 3.32% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global actinic keratosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Actinic Keratosis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Almirall
  • GALDERMA
  • LEO Pharma
  • Valeant
Other prominent vendors
  • Biofrontera
  • Novartis
  • Perrigo
  • Promius Pharma
  • Taro Pharmaceutical Industries
  • TOLMAR Pharmaceuticals
  • Vidac Pharma
Market drivers
  • High prevalence of actinic keratosis
  • For a full, detailed list, view the full report
Market challenges
  • Alternative treatment options
  • For a full, detailed list, view the full report
Market trends
  • Novel drug delivery mechanisms
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Almirall
  • Biofrontera
  • GALDERMA
  • LEO Pharma
  • Novartis
  • Perrigo
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: DISEASE OVERVIEW
  • Actinic keratosis
PART 06: MARKET LANDSCAPE
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY DRUG CLASS
  • Nucleoside metabolic inhibitors
  • Immunomodulators
  • Photosensitizers
  • NSAIDs
PART 09: REGIONAL LANDSCAPE
  • Regional comparison
  • Actinic keratosis drugs market in Americas
  • Actinic keratosis drugs market in EMEA
  • Actinic keratosis drugs market in APAC
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Novel drug delivery mechanisms
  • Advanced diagnostic techniques
  • Drug development by 3D tissue modelling
  • Industry focus on actinic keratosis R&D activity
  • Development of targeted drugs having selectivity to cells
PART 13: VENDOR LANDSCAPE
  • Almirall
  • GALDERMA
  • LEO Pharma
  • Valeant
  • Other prominent vendors
PART 14: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Global actinic keratosis drugs market
Exhibit 02: Global actinic keratosis drugs market 2016-2021 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Pipeline landscape by development phase
Exhibit 05: Key clinical trials
Exhibit 06: Global actinic keratosis drugs market by drug class 2016
Exhibit 07: Global actinic keratosis drugs market by drug class 2021
Exhibit 08: Global actinic keratosis drugs market by nucleoside metabolic inhibitors 2016-2021 ($ millions)
Exhibit 09: Global actinic keratosis drugs market by immunomodulators 2016-2021 ($ millions)
Exhibit 10: Global actinic keratosis drugs market by photosensitizers 2016-2021 ($ millions)
Exhibit 11: Global actinic keratosis drugs market by NSAIDs 2016-2021 ($ millions)
Exhibit 12: Global actinic keratosis drugs market by geography 2016-2021 (% share)
Exhibit 13: Regional comparison
Exhibit 14: Actinic keratosis drugs market in Americas 2016-2021 ($ millions)
Exhibit 15: Actinic keratosis drugs market in Americas - Year over year growth 2017-2021
Exhibit 16: Actinic keratosis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 17: Actinic keratosis drugs market in EMEA - Year over year growth 2017-2021
Exhibit 18: Actinic keratosis drugs market in APAC 2016-2021 ($ millions)
Exhibit 19: Actinic keratosis drugs market in APAC - Year over year growth 2017-2021
Exhibit 20: Key leading countries
Exhibit 21: Almirall: Key highlights
Exhibit 22: Almirall: Strength assessment
Exhibit 23: Almirall: Strategy assessment
Exhibit 24: Almirall: Opportunity assessment
Exhibit 25: GALDERMA: Key highlights
Exhibit 26: GALDERMA: Strength assessment
Exhibit 27: GALDERMA: Strategy assessment
Exhibit 28: GALDERMA: Opportunity assessment
Exhibit 29: LEO Pharma: Key highlights
Exhibit 30: LEO Pharma: Strength assessment
Exhibit 31: LEO Pharma: Strategy assessment
Exhibit 32: LEO Pharma: Opportunity assessment
Exhibit 33: Valeant: Key highlights
Exhibit 34: Valeant: Strength assessment
Exhibit 35: Valeant: Strategy assessment
Exhibit 36: Valeant: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Almirall
  • Biofrontera
  • GALDERMA
  • LEO Pharma
  • Novartis
  • Perrigo
  • MORE
New Report Released: - Global Actinic Keratosis Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global actinic keratosis drugs market: Almirall, GALDERMA, LEO Pharma, and Valeant.

Other Prominent Vendors in the market are: Biofrontera, Novartis, Perrigo, Promius Pharma, Taro Pharmaceutical Industries, TOLMAR Pharmaceuticals, and Vidac Pharma.

Commenting on the report, an analyst from the research team said: “One trend in the market is novel drug delivery mechanisms. The advent of novel drug delivery systems such as microneedles will improve the efficacy and bioavailability of the already marketed formulations. Microneedling has evolved as an adjuvant therapy to the drug treatment available for actinic keratosis.”

According to the report, one driver in the market is high prevalence of actinic keratosis. Actinic keratosis develops mainly due to UV exposure. The lesions arising from actinic keratosis can lead to squamous cell carcinoma if left untreated. With the growing awareness of oncology, people believe in choosing causative treatment. This leads to a higher incidence rate of actinic keratosis treatment, which has been driving the market growth. The prevalence is high in individuals with fair skin and in regions with high exposure to the sun such as those near the equator. As per the NIH, the prevalence rate of actinic keratosis was estimated to be 40%-50% in the Caucasian population aged above 40 years.

Further, the report states that one challenge in the market is alternative treatment options. The availability of better alternative treatment modalities is the biggest challenge for the global actinic keratosis drugs market. The treatment of actinic keratosis through techniques such as cryotherapy and chemical peeling is more popular than treatment through drugs due to their better efficacy. Cryotherapy freezes the cells affected by actinic keratosis by applying liquid nitrogen to the area and thereby stops the disease growth. Considering that such quick therapies save on time and are convenient for patients, their popularity is only expected to grow over time.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Almirall
  • GALDERMA
  • LEO Pharma
  • Valeant
  • Biofrontera
  • Novartis
  • Perrigo
  • Promius Pharma
  • Taro Pharmaceutical Industries
  • TOLMAR Pharmaceuticals
  • Vidac Pharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll